Illumina (ILMN) Stock Price, News & Analysis

Company Overview

Illumina, Inc. is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company’s offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data. Illumina also provides related services and support for laboratories and research organizations.

Founded in 1998 and headquartered in San Diego, California, Illumina serves customers worldwide, including academic and government research institutions, hospitals, clinical laboratories, biotechnology and pharmaceutical companies, and other organizations involved in genomics. The company has operated internationally through regional offices, distributors and support networks. Jacob Thaysen has served as Illumina’s chief executive officer since September 2023.

Key Stats

• Today's Range: $231.18 to $256.09
• 50-Day Range: $201.27 to $293.69
• 52-Week Range: $106.12 to $309.35
• Volume: 5.39 million shs
• Average Volume: 2.36 million shs
• Market Capitalization: $35.63 billion
• P/E Ratio: 40.62
• Dividend Yield: N/A
• Price Target: $238.53
• Consensus Rating: Hold

Illumina Stock Analysis - MarketRank™

Illumina scored higher than 52% of companies evaluated by MarketBeat, and ranked 538th out of 896 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.2 / 5
• Analyst Rating: Hold

Consensus Rating

Illumina has received a consensus rating of Hold. The company's average rating score is 2.32, and is based on no strong buy ratings, 9 buy ratings, 7 hold ratings, and 3 sell ratings.

Upside/Downside

The consensus price target for Illumina is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Illumina has been the subject of 16 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 14.18%

Earnings Growth

Earnings for Illumina are expected to grow by 14.18% in the coming year, from $5.36 to $6.12 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Illumina is 40.62, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 26.05.

Price to Earnings Ratio vs. Sector

The P/E ratio of Illumina is 40.62, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 36.02.

Price to Earnings Growth Ratio

Illumina has a PEG Ratio of 4.11. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Illumina has a P/B Ratio of 13.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.38% of the float of Illumina has been sold short.

Short Interest Ratio / Days to Cover

Illumina has a short interest ratio ("days to cover") of 2.94, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Illumina has recently decreased by 16.75%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Illumina does not currently pay a dividend.

Dividend Growth

Illumina does not have a long track record of dividend growth.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 0.66

News Sentiment

Illumina has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 61 news articles for Illumina this week, compared to 9 articles on an average week.

Search Interest

22 people have searched for ILMN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

18 people have added Illumina to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Illumina insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $436,356,102.00 in company stock.

Percentage Held by Insiders

2.90% of the stock of Illumina is held by insiders.

Percentage Held by Institutions

89.42% of the stock of Illumina is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 10/29/2026
• Today: 10/30/2026
• UBS Global Healthcare Conference: 11/10/2026
• Jefferies Global Healthcare Conference: 11/17/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:ILMN
• CIK: 1110803
• Web: www.illumina.com
• Phone: (858) 202-4500
• Fax: 858-202-4766
• Employees: 8,650
• Year Founded: 1998

Price Target and Rating

• Average Price Target for Illumina: $238.53
• High Price Target: $310.00
• Low Price Target: $113.00
• Potential Upside/Downside: +1.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.32
• Research Coverage: 19 Analysts

Profitability

• EPS (Trailing Twelve Months): $5.81
• Trailing P/E Ratio: 40.62
• Forward P/E Ratio: 44.03
• P/E Growth: 4.11
• Net Income: $850 million
• Net Margins: 19.72%
• Pretax Margin: 22.59%
• Return on Equity: 29.41%
• Return on Assets: 12.20%

Debt

• Debt-to-Equity Ratio: 0.53
• Current Ratio: 1.80
• Quick Ratio: 1.40

Sales & Book Value

• Annual Sales: $4.34 billion
• Price / Sales: 8.21
• Cash Flow: $5.46 per share
• Price / Cash Flow: 43.20
• Book Value: $17.82 per share
• Price / Book: 13.24

Miscellaneous

• Outstanding Shares: 151,000,000
• Free Float: 146,621,000
• Market Cap: $35.63 billion
• Optionable: Optionable
• Beta: 1.41